Platelet Concentrate
drug drugOn this page
Summary
Platelet Concentrate (CHEMBL2108774) is a phase-3 clinical-stage unknown; indicated across 3 conditions including autoimmune thrombocytopenic purpura and hematopoietic and lymphoid system neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108774 |
| Name | Platelet Concentrate |
| Type | Unknown |
| Max phase | 3 |
Also known as: Platelet concentrate, PLATELET CONCENTRATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| autoimmune thrombocytopenic purpura | 3 | MONDO:0008558 | EFO:0007160 |
| hematopoietic and lymphoid system neoplasm | 2 | MONDO:0002334 | MONDO:0044881 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05667805 | PHASE4 | RECRUITING | Coagulation in Cirrhosis |
| NCT01955811 | PHASE4 | COMPLETED | Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion |
| NCT03492515 | PHASE3 | UNKNOWN | Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia |
| NCT03196310 | Not specified | TERMINATED | Single Blinded First CMC Osteoarthritis Treatment |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: autoimmune thrombocytopenic purpura, hematopoietic and lymphoid system neoplasm